Viva Biotech Holdings (HKG:1873)
1.890
-0.030 (-1.56%)
Apr 17, 2026, 1:02 PM HKT
Viva Biotech Holdings Employees
Viva Biotech Holdings had 2,169 employees as of December 31, 2025. The number of employees increased by 106 or 5.14% compared to the previous year.
Employees
2,169
Change
106
Growth
5.14%
Revenue / Employee
887.30K HKD
Profits / Employee
112.75K HKD
Market Cap
4.05B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,169 | 106 | 5.14% |
| Jun 30, 2025 | 2,085 | - | - |
| Dec 31, 2024 | 2,063 | -14 | -0.67% |
| Dec 31, 2023 | 2,077 | -524 | -20.15% |
| Dec 31, 2022 | 2,601 | 474 | 22.28% |
| Dec 31, 2021 | 2,127 | 508 | 31.38% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AIM Vaccine | 1,466 |
| Shandong Boan Biotechnology | 714 |
| BioDlink International Company | 613 |
| Jiangsu Recbio Technology | 491 |
| Mirxes Holding Company | 347 |
| Qyuns Therapeutics | 337 |
| Clover Biopharmaceuticals | 243 |
| Beijing Luzhu Biotechnology | 205 |
Viva Biotech Holdings News
- 17 days ago - Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up - PRNewsWire
- 4 weeks ago - Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA - PRNewsWire
- 3 months ago - Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities - PRNewsWire
- 4 months ago - Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. - PRNewsWire
- 7 months ago - Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry - PRNewsWire
- 8 months ago - Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights - PRNewsWire
- 8 months ago - Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth - PRNewsWire
- 1 year ago - Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection - PRNewsWire